Journal of Cancer Therapy
Vol.3 No.4(2012), Paper ID 21589, 11
pages
DOI:10.4236/jct.2012.34035
Preclinical Efficacy of Nimotuzumab, an Anti-Egfr Monoclonal Antibody as a Single Agent Therapy in Human GBM u87mg Xenografts
Arlhee Diaz, Rances Blanco, Margit Lemm, Iduna Fichtner, Kalet Leon, Enrique Montero
Center of Molecular Immunology; Havana, Cuba
Center of Molecular Immunology; Havana, Cuba
Max Delbrück Center for Molecular Medicine. Berlin, Germany
Max Delbrück Center for Molecular Medicine. Berlin, Germany
Center of Molecular Immunology; Havana, Cuba
Center of Molecular Immunology; Havana, Cuba
Copyright © 2012 Arlhee Diaz, Rances Blanco, Margit Lemm, Iduna Fichtner, Kalet Leon, Enrique Montero et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
A. Diaz, R. Blanco, M. Lemm, I. Fichtner, K. Leon and E. Montero, "Preclinical Efficacy of Nimotuzumab, an Anti-Egfr Monoclonal Antibody as a Single Agent Therapy in Human GBM u87mg Xenografts,"
Journal of Cancer Therapy, Vol. 3 No. 4, 2012, pp. 245-255. doi:
10.4236/jct.2012.34035.